Member Info for Matml74

I understand your frustrated Tom but there was an RNS yesterday. What more do you want? SD does not control the SP and I would be concerned that he is the right man for the job if he was even worried about it at the moment. The job of the CEO is to get on with running the business. If he is doing this correctly then the business will increase in value and it will be reflected in the SP.

The guy has been at the job for just over two weeks and we have applied for a new licence and have the details on the juri exploration work. Think he is doing a great job myself.

This is not what is happening. Mologic and GAD are manufacturing the Avacta LFD affirmers and all, the same as what BBI, Avingdon and eventually Omega will be doing.

I'm with you on that David.

Data analysis for the P2 hospital trial took 54 days from the RNS notifying recruitment complete. That puts us into mid march territory for results. RM stated Q2 and I am sure he has done this to allow for Activ-2 to also report on P2 of that trial.

The next RNS will be a blockbuster.

Andy, Think your first sentence sums up what is going on. The drop is pretty much across the board in my portfolio even for companies like SLP who are printing money for fun.

Not sure how RM would do anything to try an support the SP. He didn't bother in November and we know they were in discussions with suitors then. The value here will be determined when the results are presented from all trials and I am sure that is his focus.

GL

I'm with you SS. So much incoming news with the first and most likely a move from P2 to P3 on active trial which is the precursor to EUA.

The whole market is down apart from the debt riddled leisure sector which still won't have any customers before the middle of the year. Crazy.

https://thefrontierpost.com/scientists-researching-the-genes-and-blood-of-virus-resilient-people-in-hopes-to-find-pandemics-achilles-heel/?utm_source=rss&utm_medium=rss&utm_campaign=scientists-researching-the-genes-and-blood-of-virus-resilient-people-in-hopes-to-find-pandemics-achilles-heel

InfinisandBeyond, The journalist didn't get it wrong. It was an update from DHSC spokesperson that stated the issue with Saliva test.

Fruits, I expect SNG will provide some in vitro data on the variants to further support it's case of being virus agnostic, but yes this is the real USP of SNG001.

Virus agnostic!

Well said Phil. The UK governments roadmap is even stressing the importance of therapeutics ......

" Effective treatments continue to be vital in reducing the risk to lives and of serious illness. Therapeutics are also invaluable for those in whom the vaccine does not prevent disease."

" More results are expected for medications used to help regulate or normalise the immune system, anticoagulants, anti-virals, and therapeutic antibodies for use by patients in different stages of the illness and various care settings, including hospitals and intensive care, primary care and care homes. The Government is also monitoring whether prophylactic therapies could reduce the number of patients vulnerable to COVID-19 despite vaccination, as well as therapies for those who continue to suffer the effects of COVID-19."

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963491/COVID-19_Response_-_Spring_2021.pdf

Nothing has changed here. Many of us have been through this prior to P2 readout, these pathetic antics from troll posters and forced drops in the SP. I firmly believe that SNG001 and the company has a whole is in a much further better place now than it was on July 19th 2020 where it would see a 500% rise the following morning. Switch off and ignore the noise of this BB. Just a little more patience required. GL

Testing with LFd's will be here for a long time. Key points in roadmap doc...

" A new Community Collect model will be launching so that families, small businesses and the self-employed - who have found it harder to access regular testing - can take away rapid tests from some Government and local authority sites. People will also soon be able to have rapid lateral flow tests delivered straight to their home, allowing them to carry out tests when it is most convenient. This will provide ready access to rapid lateral flow tests for those who require access to regular testing."

"As regular testing will have a key role to play in future, the Government is working to establish an effective private market for tests. Providers must meet a regulatory framework so that the public can have confidence in these tests and the Government will set up new validation processes for new tests to the private market."

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963491/COVID-19_Response_-_Spring_2021.pdf

Thanks Tim. Hopefully some clues on how recruitment is going.

Have you got Joe B’s number. Better call him and tell him to stop wasting those 10’s of millions of dollars trialling this drug.

I thought you coc@s has given up. Oh well more days of green boxes ahead by the looks of it.

Ok mate. Sorry if came across abruptly.

What are you talking about. The document publishes the SNG001 lancet data which were very good. The below is taken straight from your link!

"Monk et al. 2020 published results from randomised, double-blind, placebo- controlled, phase 2 pilot trial at nine UK sites (NCT04385095) [106]. 101 COVId-19 hospitalized adult patients were randomly assigned (1:1) to receive inhaled nebulised interferon beta-1a (SNG001) (6 MIU) or placebo by inhalation via a mouthpiece daily for 14 days. 66 (67%) patients required oxygen

supplementation at baseline: 29 in the placebo group and 37 in the SNG001 group. Patients receiving SNG001 had greater odds of improvement on the OSCI scale (odds ratio 2·32 [95% CI 1·07–5·04]; p=0·033) on day 15 or 16 and were more likely than those receiving placebo to recover to an OSCI score of 1 (no limitation of activities) during treatment (hazard ratio 2·19 [95% CI 1·03– 4·69]; p=0·043). No significant difference was found between treatment groups in the odds of hospital discharge by day 28: 39 (81%) of 48 patients had been discharged in the nebulised interferon beta-1a group compared with 36 (75%) of 48 in the placebo group (OR 1·84 [95% CI 0·64–5·29]; p=0·26). There was no significant difference between treatment groups in the odds of intubation or the time to intubation or death. SNG001 was well tolerated: the most frequently reported treatment-emergent adverse event was headache (seven [15%] patients in the SNG001 group and five [10%] in the placebo group). There were three deaths in the placebo group and none in the SNG001 group."

By the time you get the answers to all those questions sp will be a long way north of here. Everyone’s risk profile is different and looks to me like yours is best suited to ftse shares.......

Exactly Ray.

40 days into a P3 trial
33 days since P2 home trial completed
11 days into Activ-2 trial

Our time is coming very soon. All that is required is 5-6 weeks of patience.

Alinz, The stats only count deaths within 28 days of positive covid test. The definition was changed last August and reduced the death toll by about 7k at the time. There was a small study in the US last year where hospitalised patients were followed up after release and the death rate for those released from hospital found a similar result.

https://www.contagionlive.com/view/discharged-covid-19-patients-dead-readmitted-60-days

Virus can persist and mutate within immunocompromised patient!

https://www.nature.com/articles/s41375-021-01175-8?error=cookies_not_supported&code=b2685dc2-4ae4-46ba-989c-45b4fbd88aff

No. That is injected Interferon beta.